Proveca and Tanner Pharma initiate global Managed Access Program for Sialanar®

For Immediate Release

Lindsey Stevens
Tanner Pharma Group

CHARLOTTE, N.C. – Tanner Pharma Group’s Managed Access Programs (MAP) division and Proveca have agreed to launch a Managed Access Program for an oral formulation of glycopyrronium (Sialanar®) outside Europe and the USA. Sialanar is for the treatment of sialorrhea, or chronic drooling, in pediatric patients.

Sialorrhea results in the unintentional loss of saliva from the mouth and is considered abnormal in children older than three years. It is most significantly observed in patients with cerebral palsy and other neurodevelopmental disabilities.

Glycopyrronium bromide is a high affinity muscarinic receptor antagonist used to suppress salivation in children. Sialanar received a European Medicines Agency pediatric-use marketing authorization in September 2016 due to the current unavailability of a licensed oral
formulation of glycopyrronium for the treatment of sialorrhea in pediatric patients.

The program allows physicians to request Sialanar for individual patients for whom alternative treatment options are not currently available. This enables patients outside of Europe to benefit from Sialanar ahead of a potential marketing approval in their country.

Rob Keel, Global Director of Managed Access Programs, of Tanner Pharma said:

“There is a large unmet need for providing treatment options to children with sialorrhea as the pediatric population has thus far been underserved. Tanner Pharma and Proveca share a common view of wanting to enable patients in need with access to available medicines, regardless of where they live or whether a medicine is licensed in their market. Tanner Pharma provides patients access to unlicensed medicines in over 130 countries where no other treatment options are available, and the needs of patients and Proveca align well with the capabilities and mission at Tanner Pharma.”

Simon Bryson, Managing Director of Proveca said:

“We are pleased to be working with Tanner on this strategically important partnership. The collaboration strengthens Proveca’s objective in leading the way in the development and supply of medicines for children, and provides us with a significant opportunity to expand our business globally.”

Healthcare professionals can obtain details about the Sialanar® Managed Access Program by calling a Tanner Pharma representative at +44 (0) 1727 884 587 or emailing

About Proveca

Proveca Ltd is a specialist UK pharmaceutical company developing and licensing off-patent medicines to improve the lives of children in Europe, many of whom have chronic conditions requiring long term drug treatment.

Proveca is leading the way in licensing children’s medicines using the European regulatory framework, the Pediatric Use Marketing Authorization (PUMA) process. The regulation was specifically designed to increase the number of off-patent medicines being developed and licensed for children.

Proveca seeks to provide children with the medicines they need in an appropriate format and with a valid license throughout Europe. Utilizing the experiences and needs of children, their carers and their doctors, Proveca seeks to tailor the features and benefits of its products to the specific requirements of children.

Learn more by visiting

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.